{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:07:48Z","timestamp":1792508868957,"version":"4.5.0"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10787-025-01906-8","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T09:31:44Z","timestamp":1755250304000},"page":"4965-4996","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Recent advances in the therapeutics and modes of action of a range of agents used to treat ulcerative colitis and related inflammatory conditions"],"prefix":"10.1007","volume":"33","author":[{"given":"Alka","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9013-9839","authenticated-orcid":false,"given":"Parag","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ajazuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"issue":"6","key":"1906_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/psc.70016","volume":"31","author":"K Achilleos","year":"2025","unstructured":"Achilleos K, Petrou C, Nicolaidou V, Sarigiannis Y (2025) Beyond efficacy: ensuring safety in peptide therapeutics through immunogenicity assessment. J Pept Sci 31(6):e70016. https:\/\/doi.org\/10.1002\/psc.70016","journal-title":"J Pept Sci"},{"issue":"September","key":"1906_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2022.999001","volume":"13","author":"M Afzaal","year":"2022","unstructured":"Afzaal M, Saeed F, Shah YA, Hussain M, Rabail R, Socol CT, Hassoun A, Pateiro M, Lorenzo JM, Rusu AV, Aadil RM (2022) Human gut microbiota in health and disease: unveiling the relationship. Front Microbiol 13(September):1\u201314. https:\/\/doi.org\/10.3389\/fmicb.2022.999001","journal-title":"Front Microbiol"},{"key":"1906_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ph15101283","author":"O Al Musaimi","year":"2022","unstructured":"Al Musaimi O, Lombardi L, Williams DR, Albericio F (2022) Strategies for improving peptide stability and delivery. Pharmaceuticals. https:\/\/doi.org\/10.3390\/ph15101283","journal-title":"Pharmaceuticals"},{"issue":"August","key":"1906_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/CEG.S375969","volume":"16","author":"T Alameel","year":"2023","unstructured":"Alameel T, Almutairdi A, Al-Bawardy B (2023) Emerging therapies for ulcerative colitis: updates from recent clinical trials. Clin Exp Gastroenterol 16(August):147\u2013167. https:\/\/doi.org\/10.2147\/CEG.S375969","journal-title":"Clin Exp Gastroenterol"},{"key":"1906_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1570712","author":"H Al-jaber","year":"2025","unstructured":"Al-jaber H, Biswas KH, Al-mansoori L (2025) Advancing targeted therapy for colorectal cancer: harnessing ligand-directed enzyme prodrug therapy for highly speci fi c interventions. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2025.1570712","journal-title":"Front Oncol"},{"issue":"2","key":"1906_CR6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.gastha.2023.11.001","volume":"3","author":"J Angkeow","year":"2024","unstructured":"Angkeow J, Rothman A, Chaaban L, Paul N, Melia J (2024) Systematic review: outcome prediction in acute severe ulcerative colitis. Gastro Hep Advances 3(2):260\u2013270. https:\/\/doi.org\/10.1016\/j.gastha.2023.11.001","journal-title":"Gastro Hep Advances"},{"issue":"8","key":"1906_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nano11082035","volume":"11","author":"JC Antunes","year":"2021","unstructured":"Antunes JC, Seabra CL, Domingues JM, Teixeira MO, Nunes C, Costa-Lima SA, Homem NC, Reis S, Amorim MTP, Felgueiras HP (2021) Drug targeting of inflammatory bowel diseases by biomolecules. Nanomaterials 11(8):1\u201325. https:\/\/doi.org\/10.3390\/nano11082035","journal-title":"Nanomaterials"},{"key":"1906_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17040397","author":"KC Baral","year":"2025","unstructured":"Baral KC, Choi KY (2025) Barriers and strategies for oral peptide and protein therapeutics delivery: update on clinical advances. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics17040397","journal-title":"Pharmaceutics"},{"issue":"7","key":"1906_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph14070637","volume":"14","author":"I Ben Ghezala","year":"2021","unstructured":"Ben Ghezala I, Charkaoui M, Michiels C, Bardou M, Luu M (2021) Small molecule drugs in inflammatory bowel diseases. Pharmaceuticals 14(7):1\u201320. https:\/\/doi.org\/10.3390\/ph14070637","journal-title":"Pharmaceuticals"},{"key":"1906_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.10.001","author":"MV B\u00e9nard","year":"2024","unstructured":"B\u00e9nard MV, de Goffau MC, Blonk J, Hugenholtz F, van Buuren J, Paramsothy S, Kaakoush NO, Dhaens GRAM, Borody TJ, Kamm MA, Ponsioen CY (2024) Gut microbiota features in relation to fecal microbiota transplantation outcome in ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2024.10.001","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1906_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117177","volume":"178","author":"NK Bhol","year":"2024","unstructured":"Bhol NK, Bhanjadeo MM, Singh AK, Dash UC, Ojha RR, Majhi S, Duttaroy AK, Jena AB (2024) The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds. Biomed Pharmacother 178:117177. https:\/\/doi.org\/10.1016\/j.biopha.2024.117177","journal-title":"Biomed Pharmacother"},{"key":"1906_CR12","doi-asserted-by":"publisher","first-page":"1477187","DOI":"10.3389\/fmicb.2024.1477187","volume":"15","author":"NK Bhutta","year":"2024","unstructured":"Bhutta NK, Xu X, Jian C, Wang Y, Liu Y, Sun J, Han B, Wu S, Javeed A (2024) Gut microbiota mediated T cells regulation and autoimmune diseases. Front Microbiol 15:1477187. https:\/\/doi.org\/10.3389\/fmicb.2024.1477187","journal-title":"Front Microbiol"},{"key":"1906_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2025.102645","volume":"61","author":"L Blagojevic","year":"2025","unstructured":"Blagojevic L, Kamaly N (2025) Nanogels: a chemically versatile drug delivery platform. Nano Today 61:102645. https:\/\/doi.org\/10.1016\/j.nantod.2025.102645","journal-title":"Nano Today"},{"issue":"8","key":"1906_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines11082249","volume":"11","author":"E Bretto","year":"2023","unstructured":"Bretto E, Ribaldone DG, Caviglia GP, Saracco GM, Bugianesi E, Frara S (2023) Inflammatory bowel disease: emerging therapies and future treatment strategies. Biomedicines 11(8):1\u201333. https:\/\/doi.org\/10.3390\/biomedicines11082249","journal-title":"Biomedicines"},{"issue":"9","key":"1906_CR15","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.cgh.2022.06.030","volume":"21","author":"MJ Buie","year":"2023","unstructured":"Buie MJ, Quan J, Windsor JW, Coward S, Hansen TM, King JA, Kotze PG, Gearry RB, Ng SC, Mak JWY, Abreu MT, Rubin DT, Bernstein CN, Banerjee R, Yamamoto-Furusho JK, Panaccione R, Seow CH, Ma C, Underwood FE, Ahuja V, Panaccione N, Shaheen A-A, Holroyd-Leduc J, Kaplan GG, Balderramo D, Chong VH, Juliao-Ba\u00f1os F, Dutta U, Simadibrata M, Kaibullayeva J, Sun Y, Hilmi I, Raja Ali RA, Paudel MS, Altuwaijri M, Hartono JL, Wei SC, Limsrivilai J, El Ouali S, Vergara BI, Dao VH, Kelly P, Hodges P, Miao Y, Li M (2023) Global hospitalization trends for Crohn\u2019s disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses. Clin Gastroenterol Hepatol 21(9):2211\u20132221. https:\/\/doi.org\/10.1016\/j.cgh.2022.06.030","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1906_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jff.2022.105181","volume":"95","author":"M Caban","year":"2022","unstructured":"Caban M, Lewandowska U (2022) Polyphenols and the potential mechanisms of their therapeutic benefits against inflammatory bowel diseases. J Funct Foods 95:105181. https:\/\/doi.org\/10.1016\/j.jff.2022.105181","journal-title":"J Funct Foods"},{"issue":"18","key":"1906_CR17","doi-asserted-by":"publisher","first-page":"11204","DOI":"10.1021\/acsami.6b02594","volume":"8","author":"G Chen","year":"2016","unstructured":"Chen G, Xie Y, Peltier R, Lei H, Wang P, Chen J, Hu Y, Wang F, Yao X, Sun H (2016) Peptide-decorated gold nanoparticles as functional nano-capping agent of mesoporous silica container for targeting drug delivery. ACS Appl Mater Interfaces 8(18):11204\u201311209. https:\/\/doi.org\/10.1021\/acsami.6b02594","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"1906_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2023.2219427","volume":"30","author":"M Chen","year":"2023","unstructured":"Chen M, Lan H, Jin K, Chen Y (2023a) Responsive nanosystems for targeted therapy of ulcerative colitis: current practices and future perspectives. Drug Deliv 30(1):2219427. https:\/\/doi.org\/10.1080\/10717544.2023.2219427","journal-title":"Drug Deliv"},{"key":"1906_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2023.2219427","author":"M Chen","year":"2023","unstructured":"Chen M, Lan H, Jin K, Chen Y (2023b) Responsive nanosystems for targeted therapy of ulcerative colitis: current practices and future perspectives. Drug Deliv. https:\/\/doi.org\/10.1080\/10717544.2023.2219427","journal-title":"Drug Deliv"},{"key":"1906_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01452-1","author":"S Chen","year":"2023","unstructured":"Chen S, Saeed AFUH, Liu Q, Jiang Q, Xu H, Xiao GG, Rao L, Duo Y (2023c) Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-023-01452-1","journal-title":"Signal Transduct Target Ther"},{"issue":"March","key":"1906_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2025.1569328","volume":"12","author":"S Chen","year":"2025","unstructured":"Chen S, Qin Z, Zhou S, Xu Y, Zhu Y (2025) The emerging role of intestinal stem cells in ulcerative colitis. Front Med 12(March):1\u201319. https:\/\/doi.org\/10.3389\/fmed.2025.1569328","journal-title":"Front Med"},{"issue":"5","key":"1906_CR22","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1177\/2040622315586970","volume":"6","author":"LN Cherry","year":"2015","unstructured":"Cherry LN, Yunker NS, Lambert ER, Vaughan D, Lowe DK (2015) Vedolizumab: an \u03b14\u03b27 integrin antagonist for ulcerative colitis and Crohn\u2019s disease. Ther Adv Chronic Dis 6(5):224\u2013233. https:\/\/doi.org\/10.1177\/2040622315586970","journal-title":"Ther Adv Chronic Dis"},{"key":"1906_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jff.2025.106870","volume":"129","author":"U Choe","year":"2025","unstructured":"Choe U (2025) Role of dietary fiber and short-chain fatty acids in preventing neurodegenerative diseases through the gut-brain axis. J Funct Foods 129:106870. https:\/\/doi.org\/10.1016\/j.jff.2025.106870","journal-title":"J Funct Foods"},{"issue":"3","key":"1906_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.37349\/eds.2023.00011","volume":"1","author":"MG Ciulla","year":"2023","unstructured":"Ciulla MG, Civera M, Sattin S, Kumar K (2023) Nature-inspired and medicinally relevant short peptides. Expl Drug Sci 1(3):140\u2013171. https:\/\/doi.org\/10.37349\/eds.2023.00011","journal-title":"Expl Drug Sci"},{"key":"1906_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14031001","author":"M Colwill","year":"2025","unstructured":"Colwill M, Baillie S, Clough J, Pollok R, Poullis A, Patel K, Honap S (2025) Role of mirikizumab in the treatment of inflammatory bowel disease-from bench to bedside. J Clin Med. https:\/\/doi.org\/10.3390\/jcm14031001","journal-title":"J Clin Med"},{"key":"1906_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307118","author":"G D\u2019Haens","year":"2014","unstructured":"D\u2019Haens G, Sandborn W, Colombel J, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan B (2014) A phase II study of laquinimod in Crohn\u2019s disease. Gut. https:\/\/doi.org\/10.1136\/gutjnl-2014-307118","journal-title":"Gut"},{"issue":"12","key":"1906_CR27","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.str.2011.09.014","volume":"19","author":"O Dagliyan","year":"2011","unstructured":"Dagliyan O, Proctor EA, D\u2019Auria KM, Ding F, Dokholyan NV (2011) Structural and dynamic determinants of protein-peptide recognition. Structure (London, England:1993) 19(12):1837\u20131845. https:\/\/doi.org\/10.1016\/j.str.2011.09.014","journal-title":"Structure (London, England:1993)"},{"key":"1906_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/children7120307","author":"N Dan","year":"2020","unstructured":"Dan N, Samanta K, Almoazen H (2020) An update on pharmaceutical strategies for oral delivery of therapeutic peptides and proteins in adults and pediatrics. Children (Basel). https:\/\/doi.org\/10.3390\/children7120307","journal-title":"Children (Basel)"},{"issue":"2","key":"1906_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1136\/gutjnl-2014-308004","volume":"64","author":"S Danese","year":"2015","unstructured":"Danese S, Rudzi\u0144ski J, Brandt W, Dupas J-L, Peyrin-Biroulet L, Bouhnik Y, Kleczkowski D, Uebel P, Lukas M, Knutsson M, Erlandsson F, Hansen MB, Keshav S (2015) Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut 64(2):243\u2013249. https:\/\/doi.org\/10.1136\/gutjnl-2014-308004","journal-title":"Gut"},{"issue":"9","key":"1906_CR30","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3390\/pharmaceutics16091185","volume":"16","author":"A Di Rienzo","year":"2024","unstructured":"Di Rienzo A, Marinelli L, Dimmito MP, Toto EC, Di Stefano A, Cacciatore I (2024) Advancements in inflammatory bowel disease management: from traditional treatments to monoclonal antibodies and future drug delivery systems. Pharmaceutics 16(9):1185. https:\/\/doi.org\/10.3390\/pharmaceutics16091185","journal-title":"Pharmaceutics"},{"issue":"2","key":"1906_CR31","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11739-023-03374-w","volume":"19","author":"F Di Vincenzo","year":"2024","unstructured":"Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F (2024) Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med 19(2):275\u2013293. https:\/\/doi.org\/10.1007\/s11739-023-03374-w","journal-title":"Intern Emerg Med"},{"issue":"12","key":"1906_CR32","doi-asserted-by":"publisher","first-page":"4446","DOI":"10.1007\/s12325-024-03003-8","volume":"41","author":"A Dignass","year":"2024","unstructured":"Dignass A, Ainsworth C, Hartz S, Dunnewind N, Redondo I, Sapin C, Kroep S, Halfpenny N, Arc\u00e0 E, Hoque S (2024) Efficacy and safety of advanced therapies in moderately-to-severely active ulcerative colitis: a systematic review and network meta-analysis. Adv Ther 41(12):4446\u20134462. https:\/\/doi.org\/10.1007\/s12325-024-03003-8","journal-title":"Adv Ther"},{"key":"1906_CR33","doi-asserted-by":"publisher","unstructured":"Dixon J, Osman G, Morris G, Markides H, Rotherham M, Haj A, Denning C, Shakesheff K (2015) Highly efficient delivery of functional cargoes by the synergistic effect of gag binding motifs and cell-penetrating peptides. In Proceedings of the national academy of sciences, Vol 113. https:\/\/doi.org\/10.1073\/pnas.1518634113","DOI":"10.1073\/pnas.1518634113"},{"issue":"2","key":"1906_CR34","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1210\/en.2013-1871","volume":"155","author":"CX Dong","year":"2014","unstructured":"Dong CX, Zhao W, Solomon C, Rowland KJ, Ackerley C, Robine S, Holzenberger M, Gonska T, Brubaker PL (2014) The intestinal epithelial insulin-like growth factor-1 receptor links glucagon-like peptide-2 action to gut barrier function. Endocrinology 155(2):370\u2013379. https:\/\/doi.org\/10.1210\/en.2013-1871","journal-title":"Endocrinology"},{"key":"1906_CR35","doi-asserted-by":"publisher","first-page":"993","DOI":"10.2147\/IJN.S442369","volume":"19","author":"K Dong","year":"2024","unstructured":"Dong K, Zhang Y, Ji HR, Guan ZL, Wang DY, Guo ZY, Deng SJ, He BY, Xing JF, You CY (2024) Dexamethasone-loaded lipid calcium phosphate nanoparticles treat experimental colitis by regulating macrophage polarization in inflammatory sites. Int J Nanomed 19:993\u20131016. https:\/\/doi.org\/10.2147\/IJN.S442369","journal-title":"Int J Nanomed"},{"key":"1906_CR36","first-page":"2322","volume":"10","author":"N Dubey","year":"2021","unstructured":"Dubey N, Dubey G, Ali J (2021) A comprehensive review on colon targeted drug delivery system. World J Pharm Pharm Sci 10:2322\u20132340","journal-title":"World J Pharm Pharm Sci"},{"key":"1906_CR37","doi-asserted-by":"publisher","DOI":"10.1080\/25740881.2025.2499826","author":"S Dubey","year":"2025","unstructured":"Dubey S, Sanjeev Kumar P, Madhulika P, Krishna Y, Minz S (2025) A comprehensive review on polycaprolactone: a promising polymer for enhancing drug bioavailability. Polymer-Plastics Technol Mater. https:\/\/doi.org\/10.1080\/25740881.2025.2499826","journal-title":"Polymer-Plastics Technol Mater"},{"key":"1906_CR38","doi-asserted-by":"publisher","DOI":"10.1021\/ml2001455","author":"J Duffy","year":"2011","unstructured":"Duffy J, Harrington E, Salituro F, Cochran J, Green J, Gao H, Bemis G, Evindar G, Galullo V, Ford P, Germann U, Wilson K, Bellon S, Chen G, Taslimi P, Jones P, Huang C, Pazhanisamy S, Wang Y-M, Su M (2011) The discovery of VX-745: a novel and selective p38\u03b1 kinase inhibitor. ACS Med Chem Lett. https:\/\/doi.org\/10.1021\/ml2001455","journal-title":"ACS Med Chem Lett"},{"key":"1906_CR39","unstructured":"Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. (n.d.)"},{"issue":"3","key":"1906_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/psc.70001","volume":"31","author":"YY Elsayed","year":"2025","unstructured":"Elsayed YY, K\u00fchl T, Imhof D (2025) Regulatory guidelines for the analysis of therapeutic peptides and proteins. J Pept Sci 31(3):e70001. https:\/\/doi.org\/10.1002\/psc.70001","journal-title":"J Pept Sci"},{"issue":"2","key":"1906_CR41","doi-asserted-by":"publisher","first-page":"472","DOI":"10.5530\/ijper.20250937","volume":"59","author":"HS Elsewedy","year":"2025","unstructured":"Elsewedy HS (2025) Insights of nanoemulsion as a drug delivery system: an overview of current trends and applications. Indian J Pharm Educ Res 59(2):472\u2013492. https:\/\/doi.org\/10.5530\/ijper.20250937","journal-title":"Indian J Pharm Educ Res"},{"key":"1906_CR42","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ijbiomac.2022.01.063","volume":"202","author":"Y Esmaeili","year":"2022","unstructured":"Esmaeili Y, Khavani M, Bigham A, Sanati A, Bidram E, Shariati L, Zarrabi A, Jolfaie NA, Rafienia M (2022) Mesoporous silica@chitosan@gold nanoparticles as \u201con\/off\u201d optical biosensor and pH-sensitive theranostic platform against cancer. Int J Biol Macromol 202:241\u2013255. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.01.063","journal-title":"Int J Biol Macromol"},{"key":"1906_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010224","author":"J Fanizza","year":"2023","unstructured":"Fanizza J, D\u2019Amico F, Lusetti F, Fasulo E, Allocca M, Furfaro F, Zilli A, Parigi TL, Radice S, Peyrin-Biroulet L, Danese S, Fiorino G (2023) The Role of IL-23 Inhibitors in Crohn\u2019s Disease. J Clin Med. https:\/\/doi.org\/10.3390\/jcm13010224","journal-title":"J Clin Med"},{"key":"1906_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13398","author":"BG Feagan","year":"2015","unstructured":"Feagan BG, Sandborn W, D\u2019Haens G, Lee SD, Allez M, Fedorak R, Seidler U, Vermeire S, Lawrance I, Maroney A, Jurgensen C, Heath A, Chang D (2015) Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs placebo as induction therapy in active Crohn\u2019s disease. Alimentary Pharmacol Ther. https:\/\/doi.org\/10.1111\/apt.13398","journal-title":"Alimentary Pharmacol Ther"},{"key":"1906_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114174","volume":"158","author":"Z Feng","year":"2023","unstructured":"Feng Z, Kang G, Wang J, Gao X, Wang X, Ye Y, Liu L, Zhao J, Liu X, Huang H, Cao X (2023) Breaking through the therapeutic ceiling of inflammatory bowel disease: dual-targeted therapies. Biomed Pharmacother 158:114174. https:\/\/doi.org\/10.1016\/j.biopha.2022.114174","journal-title":"Biomed Pharmacother"},{"key":"1906_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092302","author":"F Ferretti","year":"2022","unstructured":"Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardizzone S (2022) An update on current pharmacotherapeutic options for the treatment of ulcerative colitis. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11092302","journal-title":"J Clin Med"},{"key":"1906_CR47","unstructured":"fmicb-14\u20131286429.pdf.crdownload. (n.d.)"},{"key":"1906_CR48","doi-asserted-by":"publisher","first-page":"7894","DOI":"10.1136\/bmj.f432","volume":"346","author":"AC Ford","year":"2013","unstructured":"Ford AC, Moayyedi P, Hanauer SB, Kirsner JB (2013) Ulcerative colitis. BMJ (Online) 346:7894. https:\/\/doi.org\/10.1136\/bmj.f432","journal-title":"BMJ (Online)"},{"key":"1906_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.718093","author":"M Fortea","year":"2021","unstructured":"Fortea M, Albert-Bayo M, Abril-Gil M, Ganda Mall J-P, Serra-Ruiz X, Henao-Paez A, Exp\u00f3sito E, Gonz\u00e1lez-Castro AM, Guagnozzi D, Lobo B, Alonso-Cotoner C, Santos J (2021) Present and future therapeutic approaches to barrier dysfunction. Front Nutr. https:\/\/doi.org\/10.3389\/fnut.2021.718093","journal-title":"Front Nutr"},{"issue":"1","key":"1906_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-67371-5","volume":"14","author":"AM Fourie","year":"2024","unstructured":"Fourie AM, Cheng X, Chang L, Greving C, Li X, Knight B, Polidori D, Patrick A, Bains T, Steele R, Allen SJ, Patch RJ, Sun C, Somani S, Bhandari A, Liu D, Huie K, Li S, Rodriguez MA, Xue X, Kannan A, Kosoglou T, Sherlock JP, Towne J, Holland MC, Modi NB (2024) JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans. Sci Rep 14(1):17515. https:\/\/doi.org\/10.1038\/s41598-024-67371-5","journal-title":"Sci Rep"},{"issue":"1","key":"1906_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-021-01716-6","volume":"21","author":"K Freeman","year":"2021","unstructured":"Freeman K, Ryan R, Parsons N, Taylor-Phillips S, Willis BH, Clarke A (2021) The incidence and prevalence of inflammatory bowel disease in UK primary care: a retrospective cohort study of the IQVIA Medical Research Database. BMC Gastroenterol 21(1):1\u20137. https:\/\/doi.org\/10.1186\/s12876-021-01716-6","journal-title":"BMC Gastroenterol"},{"key":"1906_CR52","doi-asserted-by":"crossref","unstructured":"Gisbert JP (2016) Gastroenterolog\u00eda y hepatolog\u00eda, 39(6)","DOI":"10.1016\/S0210-5705(16)30173-X"},{"issue":"7","key":"1906_CR53","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/14656566.2023.2200931","volume":"24","author":"A Goetsch","year":"2023","unstructured":"Goetsch A, D\u2019Amico F, Allocca M, Fiorino G, Furfaro F, Zilli A, Parigi TL, Radice S, Peyrin-Biroulet L, Danese S (2023) Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors. Expert Opin Pharmacother 24(7):849\u2013861. https:\/\/doi.org\/10.1080\/14656566.2023.2200931","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1906_CR54","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/2050640615593681","volume":"4","author":"T Greuter","year":"2016","unstructured":"Greuter T, Biedermann L, Rogler G, Sauter B, Seibold F (2016) Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: a case series. United Eur Gastroenterol J 4(1):97\u2013104. https:\/\/doi.org\/10.1177\/2050640615593681","journal-title":"United Eur Gastroenterol J"},{"issue":"3","key":"1906_CR55","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1053\/j.gastro.2024.08.033","volume":"168","author":"M Grover","year":"2025","unstructured":"Grover M, Vanuytsel T, Chang L (2025) Intestinal permeability in disorders of gut\u2013brain interaction: from bench to bedside. Gastroenterology 168(3):480\u2013495. https:\/\/doi.org\/10.1053\/j.gastro.2024.08.033","journal-title":"Gastroenterology"},{"issue":"43","key":"1906_CR56","doi-asserted-by":"publisher","first-page":"7402","DOI":"10.3748\/wjg.v27.i43.7402","volume":"27","author":"J Gubatan","year":"2021","unstructured":"Gubatan J, Rogalla S, Holman DR, Puntasecca CJ, Polevoi D, Rubin SJS (2021) Antimicrobial peptides and the gut microbiome in inflammatory bowel disease. World J Gastroenterol 27(43):7402\u20137422. https:\/\/doi.org\/10.3748\/wjg.v27.i43.7402","journal-title":"World J Gastroenterol"},{"issue":"37","key":"1906_CR57","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035020","volume":"102","author":"M Guo","year":"2023","unstructured":"Guo M, Wang X (2023a) Pathological mechanism and targeted drugs of ulcerative colitis: a review. Medicine (Baltimore) 102(37):e35020. https:\/\/doi.org\/10.1097\/MD.0000000000035020","journal-title":"Medicine (Baltimore)"},{"key":"1906_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jff.2024.106344","volume":"119","author":"H-X Guo","year":"2024","unstructured":"Guo H-X, Ji Z-H, Wang B-B, Ren J-W, Gao W, Yuan B (2024) Walnut peptide ameliorates DSS-induced colitis in mice by inhibiting inflammation and modulating gut microbiota. J Funct Foods 119:106344. https:\/\/doi.org\/10.1016\/j.jff.2024.106344","journal-title":"J Funct Foods"},{"issue":"5","key":"1906_CR59","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.apsb.2022.07.009","volume":"13","author":"R Han","year":"2023","unstructured":"Han R, Xiao Y, Bai Q, Choi CHJ (2023) Self-therapeutic metal-based nanoparticles for treating inflammatory diseases. Acta Pharmaceutica Sinica B 13(5):1847\u20131865. https:\/\/doi.org\/10.1016\/j.apsb.2022.07.009","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"1","key":"1906_CR60","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1128\/CMR.15.1.79-94.2002","volume":"15","author":"BA Hendrickson","year":"2002","unstructured":"Hendrickson BA, Gokhale R, Cho JH (2002) Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 15(1):79\u201394. https:\/\/doi.org\/10.1128\/CMR.15.1.79-94.2002","journal-title":"Clin Microbiol Rev"},{"issue":"March","key":"1906_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2023.1089099","volume":"10","author":"C Herrera-deGuise","year":"2023","unstructured":"Herrera-deGuise C, Serra-Ruiz X, Lastiri E, Borruel N (2023) JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases. Front Med 10(March):1\u201313. https:\/\/doi.org\/10.3389\/fmed.2023.1089099","journal-title":"Front Med"},{"issue":"1","key":"1906_CR62","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000527422","volume":"104","author":"M Higashiyama","year":"2023","unstructured":"Higashiyama M, Hokaria R (2023) New and emerging treatments for inflammatory bowel disease. Digestion 104(1):74\u201381. https:\/\/doi.org\/10.1159\/000527422","journal-title":"Digestion"},{"key":"1906_CR63","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.10.051","author":"I Hirano","year":"2018","unstructured":"Hirano I, Collins M, Assouline DY, Evans L, Gupta S, Schoepfer A, Straumann A, Safroneeva E, Grimm M, Smith H, Tompkins C, Woo A, Peach R, Frohna P, Gujrathi S, Penenberg D, Li C, Opiteck G, Olson A, Dellon E (2018) RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis. Gastroenterology. https:\/\/doi.org\/10.1053\/j.gastro.2018.10.051","journal-title":"Gastroenterology"},{"key":"1906_CR64","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1146\/annurev-physiol-060821-083306","volume":"84","author":"G-T Ho","year":"2022","unstructured":"Ho G-T, Theiss AL (2022) Mitochondria and inflammatory bowel diseases: toward a stratified therapeutic intervention. Annu Rev Physiol 84:435\u2013459. https:\/\/doi.org\/10.1146\/annurev-physiol-060821-083306","journal-title":"Annu Rev Physiol"},{"issue":"1","key":"1906_CR65","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2174\/13816128130108","volume":"19","author":"S Ho","year":"2012","unstructured":"Ho S, Pothoulakis C, Wai Koon H (2012) Antimicrobial peptides and colitis. Curr Pharm des 19(1):40\u201347. https:\/\/doi.org\/10.2174\/13816128130108","journal-title":"Curr Pharm des"},{"issue":"3","key":"1906_CR66","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/mi.2010.75","volume":"4","author":"R Hontecillas","year":"2011","unstructured":"Hontecillas R, Horne WT, Climent M, Guri AJ, Evans C, Zhang Y, Sobral BW, Bassaganya-Riera J (2011) Immunoregulatory mechanisms of macrophage PPAR-\u03b3 in mice with experimental inflammatory bowel disease. Mucosal Immunol 4(3):304\u2013313. https:\/\/doi.org\/10.1038\/mi.2010.75","journal-title":"Mucosal Immunol"},{"key":"1906_CR67","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jbiotec.2022.06.006","volume":"354","author":"K Hori","year":"2022","unstructured":"Hori K, Higashida S, Osaki T, Kawano T, Inaba H, Matsuura K, Iwasaki T (2022) Intracellular delivery and photothermal therapeutic effects of polyhistidine peptide-modified gold nanoparticles. J Biotechnol 354:34\u201344. https:\/\/doi.org\/10.1016\/j.jbiotec.2022.06.006","journal-title":"J Biotechnol"},{"key":"1906_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/nano10101970","author":"H Idrees","year":"2020","unstructured":"Idrees H, Zaidi SZJ, Sabir A, Khan RU, Zhang X, Hassan S-U (2020) A review of biodegradable natural polymer-based nanoparticles for drug delivery applications. Nanomaterials. https:\/\/doi.org\/10.3390\/nano10101970","journal-title":"Nanomaterials"},{"issue":"13","key":"1906_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells12131730","volume":"12","author":"A Jefremow","year":"2023","unstructured":"Jefremow A, Neurath MF (2023) Novel small molecules in IBD: current state and future perspectives. Cells 12(13):1\u201312. https:\/\/doi.org\/10.3390\/cells12131730","journal-title":"Cells"},{"issue":"6","key":"1906_CR70","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.gastha.2024.04.014","volume":"3","author":"S Jelinsky","year":"2024","unstructured":"Jelinsky S, Lee I, Monetti M, Breitkopf S, Martz F, Kongala R, Culver J, Vo V, Xue L, Gieseck R, Dickinson C, Kasaian M, Lord JD (2024) Proteomic differences in colonic epithelial cells in ulcerative colitis have an epigenetic basis. Gastro Hep Advances 3(6):830\u2013841. https:\/\/doi.org\/10.1016\/j.gastha.2024.04.014","journal-title":"Gastro Hep Advances"},{"key":"1906_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104840","author":"LT Jensen","year":"2023","unstructured":"Jensen LT, Attfield KE, Feldmann M, Fugger L (2023) Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104840","journal-title":"EBioMedicine"},{"key":"1906_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1306068","author":"N Jiang","year":"2024","unstructured":"Jiang N, Liu Z, Wang H, Zhang L, Li M, Li G, Li C, Wang B, Zhao C, Liu L (2024) Alterations in metabolome and microbiome: new clues on cathelicidin-related antimicrobial peptide alleviates acute ulcerative colitis. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2024.1306068","journal-title":"Front Microbiol"},{"issue":"2","key":"1906_CR73","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3748\/wjg.v29.i2.310","volume":"29","author":"TO Johnson","year":"2023","unstructured":"Johnson TO, Akinsanmi AO, Ejembi SA, Adeyemi OE, Oche JR, Johnson GI, Adegboyega AE (2023) Modern drug discovery for inflammatory bowel disease: the role of computational methods. World J Gastroenterol 29(2):310\u2013331. https:\/\/doi.org\/10.3748\/wjg.v29.i2.310","journal-title":"World J Gastroenterol"},{"issue":"4","key":"1906_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics13040484","volume":"13","author":"A Karthikeyan","year":"2021","unstructured":"Karthikeyan A, Young KN, Moniruzzaman M, Beyene AM, Do K, Kalaiselvi S, Min T (2021) Curcumin and its modified formulations on inflammatory bowel disease (IBD): the story so far and future outlook. Pharmaceutics 13(4):1\u201338. https:\/\/doi.org\/10.3390\/pharmaceutics13040484","journal-title":"Pharmaceutics"},{"key":"1906_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010094","author":"M Kayal","year":"2020","unstructured":"Kayal M, Shah S (2020) Ulcerative colitis: Current and emerging treatment strategies. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9010094","journal-title":"J Clin Med"},{"issue":"12","key":"1906_CR76","doi-asserted-by":"publisher","first-page":"14633","DOI":"10.1021\/acsami.4c02243","volume":"16","author":"R Khandelia","year":"2024","unstructured":"Khandelia R, Hodgkinson T, Crean D, Brougham DF, Scholz D, Ibrahim H, Quinn SJ, Rodriguez BJ, Kennedy OD, O\u2019Byrne JM, Brayden DJ (2024) Reproducible synthesis of biocompatible albumin nanoparticles designed for intra-articular administration of celecoxib to treat osteoarthritis. ACS Appl Mater Interfaces 16(12):14633\u201314644. https:\/\/doi.org\/10.1021\/acsami.4c02243","journal-title":"ACS Appl Mater Interfaces"},{"key":"1906_CR77","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202300831","author":"HR Kim","year":"2024","unstructured":"Kim HR, Taslakjian B, Kim S, Tirrell MV, Guler MO (2024) Therapeutic peptides, proteins and their nanostructures for drug delivery and precision medicine. ChemBioChem. https:\/\/doi.org\/10.1002\/cbic.202300831","journal-title":"ChemBioChem"},{"key":"1906_CR78","doi-asserted-by":"publisher","first-page":"121364","DOI":"10.1016\/j.biomaterials.2022.121364","volume":"281","author":"NG Kotla","year":"2022","unstructured":"Kotla NG, Singh R, Baby BV, Rasala S, Rasool J, Hynes SO, Martin D, Egan LJ, Vemula PK, Jala VR, Rochev Y, Pandit A (2022) Inflammation-specific targeted carriers for local drug delivery to inflammatory bowel disease. Biomaterials 281:121364. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121364","journal-title":"Biomaterials"},{"issue":"8","key":"1906_CR79","doi-asserted-by":"publisher","first-page":"6191","DOI":"10.1021\/acs.jmedchem.2c00094","volume":"65","author":"T Kremsmayr","year":"2022","unstructured":"Kremsmayr T, Aljnabi A, Blanco-Canosa JB, Tran HNT, Emidio NB, Muttenthaler M (2022) On the utility of chemical strategies to improve peptide gut stability. J Med Chem 65(8):6191\u20136206. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00094","journal-title":"J Med Chem"},{"issue":"9","key":"1906_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101698","volume":"5","author":"S Kumar","year":"2024","unstructured":"Kumar S, Tailor D, Dheeraj A, Li W, Stefan K, Lee JM, Nelson D, Keefe BF, Schedin P, Kummar S, Coussens LM, Malhotra SV (2024) Uncovering therapeutic targets for macrophage-mediated T cell suppression and PD-L1 therapy sensitization. Cell Rep Med 5(9):101698. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101698","journal-title":"Cell Rep Med"},{"key":"1906_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00144","volume":"5","author":"K Kuroda","year":"2015","unstructured":"Kuroda K, Okumura K, Isogai H, Isogai E (2015) The human cathelicidin antimicrobial peptide LL-37 and mimics are potential anticancer drugs. Front Oncol 5:144. https:\/\/doi.org\/10.3389\/fonc.2015.00144","journal-title":"Front Oncol"},{"issue":"10","key":"1906_CR82","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.4155\/tde.14.67","volume":"5","author":"M Laksitorini","year":"2014","unstructured":"Laksitorini M, Prasasty VD, Kiptoo PK, Siahaan TJ (2014) Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers. Ther Deliv 5(10):1143\u20131163. https:\/\/doi.org\/10.4155\/tde.14.67","journal-title":"Ther Deliv"},{"issue":"9","key":"1906_CR83","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/ibd\/izy167","volume":"24","author":"A Leber","year":"2018","unstructured":"Leber A, Hontecillas R, Zoccoli-Rodriguez V, Bassaganya-Riera J (2018) Activation of LANCL2 by BT-11 ameliorates IBD by supporting regulatory T cell stability through immunometabolic mechanisms. Inflamm Bowel Dis 24(9):1978\u20131991. https:\/\/doi.org\/10.1093\/ibd\/izy167","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"1906_CR84","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5217\/ir.2015.13.1.11","volume":"13","author":"SH Lee","year":"2015","unstructured":"Lee SH (2015) Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases. Intest Res 13(1):11\u201318. https:\/\/doi.org\/10.5217\/ir.2015.13.1.11","journal-title":"Intest Res"},{"key":"1906_CR85","doi-asserted-by":"publisher","unstructured":"Lee SD, Clark-Snustad KD (2023) Ulcerative colitis. Encyclopedia of gastroenterology, Second Edition, 552\u2013574. https:\/\/doi.org\/10.1016\/B978-0-12-801238-3.65948-2","DOI":"10.1016\/B978-0-12-801238-3.65948-2"},{"key":"1906_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/nu16142302","author":"Q Li","year":"2024","unstructured":"Li Q, Wang J (2024) The effect of protein nutritional support on inflammatory bowel disease and its potential mechanisms. Nutrients. https:\/\/doi.org\/10.3390\/nu16142302","journal-title":"Nutrients"},{"issue":"5","key":"1906_CR87","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1021\/acsbiomaterials.6b00790","volume":"3","author":"Y Li","year":"2017","unstructured":"Li Y, Wang S, Fan J, Zhang X, Qian X, Zhang X, Luan J, Song P, Wang Z, Chen Q, Ju D (2017) Targeting TNF\u03b1 ameliorated cationic PAMAM dendrimer-induced hepatotoxicity via regulating NLRP3 inflammasomes pathway. ACS Biomater Sci Eng 3(5):843\u2013853. https:\/\/doi.org\/10.1021\/acsbiomaterials.6b00790","journal-title":"ACS Biomater Sci Eng"},{"key":"1906_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110486","volume":"129","author":"X Li","year":"2020","unstructured":"Li X, Lu C, Yang Y, Yu C, Rao Y (2020) Site-specific targeted drug delivery systems for the treatment of inflammatory bowel disease. Biomed Pharmacother 129:110486. https:\/\/doi.org\/10.1016\/j.biopha.2020.110486","journal-title":"Biomed Pharmacother"},{"key":"1906_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/J.CEJ.2022.136438","volume":"445","author":"X Li","year":"2022","unstructured":"Li X, Fang S, Yu Y, Yang H, Rao Y, Hong D, Lu C, Yu M, Lu X, Yu C, Zhao Q (2022) Oral administration of inflammatory microenvironment-responsive carrier-free infliximab nanocomplex for the targeted treatment of inflammatory bowel disease. Chem Eng J 445:136438. https:\/\/doi.org\/10.1016\/J.CEJ.2022.136438","journal-title":"Chem Eng J"},{"key":"1906_CR90","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.bioactmat.2023.01.015","volume":"25","author":"M Li","year":"2023","unstructured":"Li M, Liu J, Shi L, Zhou C, Zou M, Fu D, Yuan Y, Yao C, Zhang L, Qin S, Liu M, Cheng Q, Wang Z, Wang L (2023) Gold nanoparticles-embedded ceria with enhanced antioxidant activities for treating inflammatory bowel disease. Bioact Mater 25:95\u2013106. https:\/\/doi.org\/10.1016\/j.bioactmat.2023.01.015","journal-title":"Bioact Mater"},{"key":"1906_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.123878","volume":"653","author":"W Li","year":"2024","unstructured":"Li W, Lin J, Zhou J, He S, Wang A, Hu Y, Li H, Zou L, Liu Y (2024) Hyaluronic acid-functionalized DDAB\/PLGA nanoparticles for improved oral delivery of magnolol in the treatment of ulcerative colitis. Int J Pharm 653:123878","journal-title":"Int J Pharm"},{"key":"1906_CR92","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/j.csbj.2025.05.006","volume":"27","author":"H Li","year":"2025","unstructured":"Li H, Pan M, Li Y, Cui M, Zhang M (2025a) New targets for the treatment of ulcerative colitis: Gut microbiota and its metabolites. Comput Struct Biotechnol J 27:1850\u20131863. https:\/\/doi.org\/10.1016\/j.csbj.2025.05.006","journal-title":"Comput Struct Biotechnol J"},{"issue":"2","key":"1906_CR93","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.fmre.2024.03.025","volume":"5","author":"L Li","year":"2025","unstructured":"Li L, Wang F, Zhu D, Hu S, Cheng K, Li Z (2025b) Engineering exosomes and exosome-like nanovesicles for improving tissue targeting and retention. Fundamental Research 5(2):851\u2013867. https:\/\/doi.org\/10.1016\/j.fmre.2024.03.025","journal-title":"Fundamental Research"},{"key":"1906_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00207-w","author":"Y Liang","year":"2024","unstructured":"Liang Y, Li Y, Lee C, Yu Z, Chen C, Liang C (2024) Ulcerative colitis: molecular insights and intervention therapy. Mol Biomed. https:\/\/doi.org\/10.1186\/s43556-024-00207-w","journal-title":"Mol Biomed"},{"issue":"10","key":"1906_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics14102065","volume":"14","author":"CW Lin","year":"2022","unstructured":"Lin CW, Hung CM, Chen WJ, Chen JC, Huang WY, Lu CS, Kuo ML, Chen SG (2022) New horizons of macrophage immunomodulation in the healing of diabetic foot ulcers. Pharmaceutics 14(10):1\u201315. https:\/\/doi.org\/10.3390\/pharmaceutics14102065","journal-title":"Pharmaceutics"},{"key":"1906_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2021-11-4","volume":"11","author":"E Liu","year":"2022","unstructured":"Liu E, Aslam N, Nigam G, Limdi JK (2022b) Tofacitinib and newer JAK inhibitors in inflammatory bowel disease\u2014where we are and where we are going. Drugs Context 11:1\u201317. https:\/\/doi.org\/10.7573\/dic.2021-11-4","journal-title":"Drugs Context"},{"key":"1906_CR97","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jconrel.2022.05.025","volume":"347","author":"S Liu","year":"2022","unstructured":"Liu S, Cao Y, Ma L, Sun J, Ramos-Mucci L, Ma Y, Yang X, Zhu Z, Zhang J, Xiao B (2022c) Oral antimicrobial peptide-EGCG nanomedicines for synergistic treatment of ulcerative colitis. J Controlled Release: off J Controlled Release Soc 347:544\u2013560. https:\/\/doi.org\/10.1016\/j.jconrel.2022.05.025","journal-title":"J Controlled Release: off J Controlled Release Soc"},{"key":"1906_CR98","doi-asserted-by":"publisher","unstructured":"Liu CY, Cham CM, Chang EB (2022) Epithelial wound healing in inflammatory bowel diseases. 35\u201351. https:\/\/doi.org\/10.1016\/j.trsl.2021.06.001.Epithelial","DOI":"10.1016\/j.trsl.2021.06.001.Epithelial"},{"issue":"1","key":"1906_CR99","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-024-01852-x","volume":"9","author":"P Lu","year":"2024","unstructured":"Lu P, Ruan D, Huang M, Tian M, Zhu K, Gan Z, Xiao Z (2024) Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions. Signal Transduct Target Ther 9(1):166. https:\/\/doi.org\/10.1038\/s41392-024-01852-x","journal-title":"Signal Transduct Target Ther"},{"key":"1906_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.06.036","author":"C Ma","year":"2024","unstructured":"Ma C, Solitano V, Danese S, Jairath V (2024a) The Future of Clinical Trials in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2024.06.036","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1906_CR101","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1186\/s12951-024-02896-5","volume":"22","author":"X Ma","year":"2024","unstructured":"Ma X, Yang N, Mao R, Hao Y, Li Y, Guo Y, Teng D, Huang Y, Wang J (2024b) Self-assembly antimicrobial peptide for treatment of multidrug-resistant bacterial infection. J Nanobiotechnology 22(1):668. https:\/\/doi.org\/10.1186\/s12951-024-02896-5","journal-title":"J Nanobiotechnology"},{"issue":"3","key":"1906_CR102","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/polym3031377","volume":"3","author":"HK Makadia","year":"2011","unstructured":"Makadia HK, Siegel SJ (2011) Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 3(3):1377\u20131397. https:\/\/doi.org\/10.3390\/polym3031377","journal-title":"Polymers"},{"key":"1906_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/nu16203494","author":"A Matar","year":"2024","unstructured":"Matar A, Damianos JA, Jencks KJ, Camilleri M (2024) Intestinal barrier impairment, preservation, and repair: an update. Nutrients. https:\/\/doi.org\/10.3390\/nu16203494","journal-title":"Nutrients"},{"key":"1906_CR104","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.90221.2008","author":"M McPherson","year":"2008","unstructured":"McPherson M, Wei B, Turovskaya O, Fujiwara D, Brewer S, Braun J (2008) Colitis immunoregulation by CD8+ T cell requires T cell cytotoxicity and B cell peptide antigen presentation. Am J Physiol\u2014Gastrointestinal Liver Physiol. https:\/\/doi.org\/10.1152\/ajpgi.90221.2008","journal-title":"Am J Physiol\u2014Gastrointestinal Liver Physiol"},{"issue":"1","key":"1906_CR105","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.mucimm.2022.11.001","volume":"16","author":"M Michaels","year":"2023","unstructured":"Michaels M, Madsen KL (2023) Immunometabolism and microbial metabolites at the gut barrier: lessons for therapeutic intervention in inflammatory bowel disease. Mucosal Immunol 16(1):72\u201385. https:\/\/doi.org\/10.1016\/j.mucimm.2022.11.001","journal-title":"Mucosal Immunol"},{"key":"1906_CR106","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.jconrel.2022.12.027","volume":"353","author":"J Mondal","year":"2023","unstructured":"Mondal J, Pillarisetti S, Junnuthula V, Saha M, Hwang SR, Park I, Lee Y (2023) Hybrid exosomes, exosome-like nanovesicles and engineered exosomes for therapeutic applications. J Control Release 353:1127\u20131149","journal-title":"J Control Release"},{"key":"1906_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102129","volume":"43","author":"A Muehler","year":"2020","unstructured":"Muehler A, Peelen E, Kohlhof H, Gr\u00f6ppel M, Vitt D (2020) Vidofludimus calcium, a next generation DHODH inhibitor for the treatment of relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 43:102129. https:\/\/doi.org\/10.1016\/j.msard.2020.102129","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"1906_CR108","doi-asserted-by":"publisher","first-page":"12","DOI":"10.22159\/ijap.2024v16i2.49293","volume":"16","author":"RA Muhammed","year":"2024","unstructured":"Muhammed RA, Mohammed S, Visht S, Yassen AO (2024) a Review on development of colon targeted drug delivery system. Int J Appl Pharmaceutics 16(2):12\u201327. https:\/\/doi.org\/10.22159\/ijap.2024v16i2.49293","journal-title":"Int J Appl Pharmaceutics"},{"issue":"3","key":"1906_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.103017","volume":"21","author":"H Nakase","year":"2022","unstructured":"Nakase H, Sato N, Mizuno N, Ikawa Y (2022) The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev 21(3):103017. https:\/\/doi.org\/10.1016\/j.autrev.2021.103017","journal-title":"Autoimmun Rev"},{"issue":"6","key":"1906_CR110","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S2468-1253(24)00390-X","volume":"10","author":"MF Neurath","year":"2025","unstructured":"Neurath MF, Artis D, Becker C (2025) The intestinal barrier: a pivotal role in health, inflammation, and cancer. Lancet Gastroenterol Hepatol 10(6):573\u2013592. https:\/\/doi.org\/10.1016\/S2468-1253(24)00390-X","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1906_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108402","volume":"245","author":"OH Nielsen","year":"2023","unstructured":"Nielsen OH, Boye TL, Gubatan J, Chakravarti D, Jaquith JB, LaCasse EC (2023) Selective JAK1 inhibitors for the treatment of inflammatory bowel disease. Pharmacol Ther 245:108402. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108402","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1906_CR112","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00535-015-1098-4","volume":"51","author":"R Okamoto","year":"2016","unstructured":"Okamoto R, Watanabe M (2016) Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J Gastroenterol 51(1):11\u201321. https:\/\/doi.org\/10.1007\/s00535-015-1098-4","journal-title":"J Gastroenterol"},{"issue":"3","key":"1906_CR113","doi-asserted-by":"publisher","DOI":"10.1002\/bip.70027","volume":"116","author":"V Pandey","year":"2025","unstructured":"Pandey V, Pandey T (2025) A mechanistic understanding of reactive oxygen species (ROS)-responsive bio-polymeric nanoparticles: current state, challenges and future toward precision therapeutics. Biopolymers 116(3):e70027. https:\/\/doi.org\/10.1002\/bip.70027","journal-title":"Biopolymers"},{"issue":"5","key":"1906_CR114","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3904\/kjim.2022.132","volume":"37","author":"J Park","year":"2022","unstructured":"Park J, Cheon JH (2022) Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-\u03b1. Korean J Intern Med 37(5):895\u2013905. https:\/\/doi.org\/10.3904\/kjim.2022.132","journal-title":"Korean J Intern Med"},{"issue":"1","key":"1906_CR115","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5009\/gnl14226","volume":"9","author":"SC Park","year":"2015","unstructured":"Park SC, Jeen YT (2015) Current and emerging biologics for ulcerative colitis. Gut Liver 9(1):18\u201327. https:\/\/doi.org\/10.5009\/gnl14226","journal-title":"Gut Liver"},{"key":"1906_CR116","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/j.crfs.2022.10.031","volume":"5","author":"J Pei","year":"2022","unstructured":"Pei J, Gao X, Pan D, Hua Y, He J, Liu Z, Dang Y (2022) Advances in the stability challenges of bioactive peptides and improvement strategies. Curr Res Food Sci 5:2162\u20132170. https:\/\/doi.org\/10.1016\/j.crfs.2022.10.031","journal-title":"Curr Res Food Sci"},{"issue":"11","key":"1906_CR117","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.2217\/imt.11.122","volume":"3","author":"C Perrier","year":"2011","unstructured":"Perrier C, Rutgeerts P (2011) Cytokine blockade in inflammatory bowel diseases. Immunotherapy 3(11):1341\u20131352. https:\/\/doi.org\/10.2217\/imt.11.122","journal-title":"Immunotherapy"},{"key":"1906_CR118","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-019-1453-5","author":"M Reda","year":"2019","unstructured":"Reda M, Farghaly U, Elgarhy O, Khaled K (2019) Budesonide-loaded eudragit s 100 nanocapsules for the treatment of acetic acid-induced colitis in animal model. AAPS PharmSciTech. https:\/\/doi.org\/10.1208\/s12249-019-1453-5","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"1906_CR119","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/nyas.14791","volume":"1514","author":"J Reiner","year":"2022","unstructured":"Reiner J, Thiery J, Held J, Berlin P, Skarbaliene J, Vollmar B, Jaster R, Eriksson P-O, Lamprecht G, Witte M (2022) The dual GLP-1 and GLP-2 receptor agonist dapiglutide promotes barrier function in murine short bowel. Ann N Y Acad Sci 1514(1):132\u2013141. https:\/\/doi.org\/10.1111\/nyas.14791","journal-title":"Ann N Y Acad Sci"},{"key":"1906_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2023.1217165","volume":"14","author":"DK Sahoo","year":"2023","unstructured":"Sahoo DK, Heilmann RM, Paital B, Patel A, Yadav VK, Wong D, Jergens AE (2023) Oxidative stress, hormones, and effects of natural antioxidants on intestinal inflammation in inflammatory bowel disease. Front Endocrinol 14:1\u201324. https:\/\/doi.org\/10.3389\/fendo.2023.1217165","journal-title":"Front Endocrinol"},{"issue":"2","key":"1906_CR121","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3109\/21691401.2014.975239","volume":"44","author":"KK Sahu","year":"2016","unstructured":"Sahu KK, Minz S, Kaurav M, Pandey RS (2016) Proteins and peptides: the need to improve them as promising therapeutics for ulcerative colitis. Artif Cells Nanomed Biotechnol 44(2):642\u2013653. https:\/\/doi.org\/10.3109\/21691401.2014.975239","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"4","key":"1906_CR122","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1136\/gut.2005.078055","volume":"55","author":"BE Sands","year":"2006","unstructured":"Sands BE (2006) Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories? Gut 55(4):437\u2013441. https:\/\/doi.org\/10.1136\/gut.2005.078055","journal-title":"Gut"},{"issue":"4","key":"1906_CR123","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/ecco-jcc\/jjz170","volume":"14","author":"H Schmitt","year":"2020","unstructured":"Schmitt H, Ulmschneider J, Billmeier U, Vieth M, Scarozza P, Sonnewald S, Reid S, Atreya I, Rath T, Zundler S, Langheinrich M, Sch\u00fcttler J, Hartmann A, Winkler T, Admyre C, Knittel T, Dieterich Johansson C, Zargari A, Neurath MF, Atreya R (2020) The TLR9 agonist cobitolimod induces IL10-producing wound healing macrophages and regulatory T cells in ulcerative colitis. J Crohns Colitis 14(4):508\u2013524. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz170","journal-title":"J Crohns Colitis"},{"issue":"1","key":"1906_CR124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12014-019-9224-6","volume":"16","author":"A Schniers","year":"2019","unstructured":"Schniers A, Goll R, Pasing Y, S\u00f8rbye SW, Florholmen J, Hansen T (2019) Ulcerative colitis: Functional analysis of the in-depth proteome. Clin Proteomics 16(1):1\u201313. https:\/\/doi.org\/10.1186\/s12014-019-9224-6","journal-title":"Clin Proteomics"},{"issue":"6","key":"1906_CR125","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.4049\/jimmunol.167.6.3207","volume":"167","author":"A Sch\u00f6nemeyer","year":"2001","unstructured":"Sch\u00f6nemeyer A, Lucius R, Sonnenburg B, Brattig N, Sabat R, Schilling K, Bradley J, Hartmann S (2001) Modulation of human T cell responses and macrophage functions by onchocystatin, a secreted protein of the filarial nematode Onchocerca volvulus. J Immunol 167(6):3207\u20133215. https:\/\/doi.org\/10.4049\/jimmunol.167.6.3207","journal-title":"J Immunol"},{"issue":"2","key":"1906_CR126","doi-asserted-by":"publisher","first-page":"135","DOI":"10.7861\/CLINMED.2021-0080","volume":"21","author":"JP Segal","year":"2021","unstructured":"Segal JP, Jean-Fr\u00e9d\u00e9ric LeBlanc A, Hart AL (2021) Ulcerative colitis: an update. Clin Med J R Coll Physicians Lond 21(2):135\u2013139. https:\/\/doi.org\/10.7861\/CLINMED.2021-0080","journal-title":"Clin Med J R Coll Physicians Lond"},{"key":"1906_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2016.00171","volume":"7","author":"M Shevtsov","year":"2016","unstructured":"Shevtsov M, Multhoff G (2016) Heat shock protein-Peptide and HSP-based immunotherapies for the treatment of cancer. Front Immunol 7:1\u20137. https:\/\/doi.org\/10.3389\/fimmu.2016.00171","journal-title":"Front Immunol"},{"key":"1906_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114904","volume":"199","author":"M Shi","year":"2023","unstructured":"Shi M, McHugh K (2023) Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems. Adv Drug Deliv Rev 199:114904. https:\/\/doi.org\/10.1016\/j.addr.2023.114904","journal-title":"Adv Drug Deliv Rev"},{"key":"1906_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.nxnano.2025.100184","volume":"7","author":"S Shidhaye","year":"2025","unstructured":"Shidhaye S, Nagpurkar K, Kale M, Khobragade R, Umekar M, Koche S, Trivedi R (2025) Review on biodegradable microsphere with special emphasis on inflammatory bowel disease & recent patents. Next Nanotechnology 7:100184","journal-title":"Next Nanotechnology"},{"key":"1906_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.progpolymsci.2024.101867","volume":"156","author":"RP Sivasankaran","year":"2024","unstructured":"Sivasankaran RP, Snell K, Kunkel G, Georgiou PG, Puente EG, Maynard HD (2024) Polymer-mediated protein\/peptide therapeutic stabilization: current progress and future directions. Prog Polym Sci 156:101867. https:\/\/doi.org\/10.1016\/j.progpolymsci.2024.101867","journal-title":"Prog Polym Sci"},{"issue":"48","key":"1906_CR131","doi-asserted-by":"publisher","first-page":"7593","DOI":"10.3748\/WJG.V26.I48.7593","volume":"26","author":"X Sun","year":"2020","unstructured":"Sun X, Huang Y, Zhang YL, Qiao D, Dai YC (2020) Research advances of vasoactive intestinal peptide in the pathogenesis of ulcerative colitis by regulating interleukin-10 expression in regulatory B cells. World J Gastroenterol 26(48):7593\u20137602. https:\/\/doi.org\/10.3748\/WJG.V26.I48.7593","journal-title":"World J Gastroenterol"},{"issue":"May","key":"1906_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2023.1165667","volume":"14","author":"B Thapa","year":"2023","unstructured":"Thapa B, Pak S, Chung D, Shin HK, Lee SH, Lee K (2023) Cell-penetrating TLR inhibitor peptide alleviates ulcerative colitis by the functional modulation of macrophages. Front Immunol 14(May):1\u201316. https:\/\/doi.org\/10.3389\/fimmu.2023.1165667","journal-title":"Front Immunol"},{"issue":"11","key":"1906_CR133","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1042\/BCJ20160510","volume":"474","author":"E Thursby","year":"2017","unstructured":"Thursby E, Juge N (2017) Introduction to the human gut microbiota. Biochem J 474(11):1823\u20131836. https:\/\/doi.org\/10.1042\/BCJ20160510","journal-title":"Biochem J"},{"issue":"11","key":"1906_CR134","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1136\/gutjnl-2012-303959","volume":"62","author":"J Torres","year":"2013","unstructured":"Torres J, Danese S, Colombel JF (2013) New therapeutic avenues in ulcerative colitis: thinking out of the box. Gut 62(11):1642\u20131652. https:\/\/doi.org\/10.1136\/gutjnl-2012-303959","journal-title":"Gut"},{"key":"1906_CR135","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.2147\/DDDT.S182891","volume":"13","author":"F Varyani","year":"2019","unstructured":"Varyani F, Argyriou K, Phillips F, Tsakiridou E, Moran GW (2019) Profile of tofacitinib in the treatment of ulcerative colitis: an evidence-based review of recent data. Drug des Devel Ther 13:4091\u20134105. https:\/\/doi.org\/10.2147\/DDDT.S182891","journal-title":"Drug des Devel Ther"},{"issue":"6","key":"1906_CR136","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s40121-022-00690-0","volume":"11","author":"MJGT Vehreschild","year":"2022","unstructured":"Vehreschild MJGT, Atanasov P, Yurko K, Oancea C, Popov G, Smesnoi V, Placinta G, Kohlhof H, Vitt D, Peelen E, Mihajlovi\u0107 J, Muehler AR (2022) Safety and efficacy of vidofludimus calcium in patients hospitalized with COVID-19: a double-blind, randomized, placebo-controlled, phase 2 trial. Infect Dis Ther 11(6):2159\u20132176. https:\/\/doi.org\/10.1007\/s40121-022-00690-0","journal-title":"Infect Dis Ther"},{"key":"1906_CR137","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020608","author":"SHC Veltkamp","year":"2025","unstructured":"Veltkamp SHC, Voorneveld PW (2025) The cell-specific effects of JAK1 inhibitors in ulcerative colitis. J Clin Med. https:\/\/doi.org\/10.3390\/jcm14020608","journal-title":"J Clin Med"},{"key":"1906_CR138","unstructured":"Version of Record: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1773224724000935. (2024)."},{"issue":"8","key":"1906_CR139","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/bph.14178","volume":"176","author":"JL Wallace","year":"2019","unstructured":"Wallace JL (2019) Eicosanoids in the gastrointestinal tract. Br J Pharmacol 176(8):1000\u20131008. https:\/\/doi.org\/10.1111\/bph.14178","journal-title":"Br J Pharmacol"},{"key":"1906_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117302","volume":"179","author":"X Wang","year":"2024","unstructured":"Wang X, Peng J, Cai P, Xia Y, Yi C, Shang A, Akanyibah FA, Mao F (2024) The emerging role of the gut microbiota and its application in inflammatory bowel disease. Biomed Pharmacother 179:117302. https:\/\/doi.org\/10.1016\/j.biopha.2024.117302","journal-title":"Biomed Pharmacother"},{"key":"1906_CR141","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-019-01098-8","author":"D Wu","year":"2020","unstructured":"Wu D, Chen Y, Sun Y, Gao Q, Li H, Yang Z, Wang Y, Jiang X, Yu B (2020) Target of MCC950 in inhibition of NLRP3 inflammasome activation: a literature review. Inflammation. https:\/\/doi.org\/10.1007\/s10753-019-01098-8","journal-title":"Inflammation"},{"issue":"12","key":"1906_CR142","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.7150\/thno.15710","volume":"6","author":"B Xiao","year":"2016","unstructured":"Xiao B, Zhang Z, Viennois E, Kang Y, Zhang M, Han MK, Chen J, Merlin D (2016) Combination therapy for ulcerative colitis: Orally targeted nanoparticles prevent mucosal damage and relieve inflammation. Theranostics 6(12):2250\u20132266. https:\/\/doi.org\/10.7150\/thno.15710","journal-title":"Theranostics"},{"issue":"10","key":"1906_CR143","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.1039\/D3FO04413K","volume":"15","author":"W-Y Xie","year":"2024","unstructured":"Xie W-Y, Ji Z-H, Ren W-Z, Zhao P-S, Wei F-H, Hu J, Yuan B, Gao W (2024) Wheat peptide alleviates DSS-induced colitis by activating the Keap1\u2013Nrf2 signaling pathway and maintaining the integrity of the gut barrier. Food Funct 15(10):5466\u20135484. https:\/\/doi.org\/10.1039\/D3FO04413K","journal-title":"Food Funct"},{"issue":"1","key":"1906_CR144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41538-024-00367-7","volume":"9","author":"XY Xin","year":"2025","unstructured":"Xin XY, Zhou J, Liu GG, Zhang MY, Li XZ, Wang Y (2025a) Anti-inflammatory activity of collagen peptide in vitro and its effect on improving ulcerative colitis. NPJ Sci Food 9(1):1\u201313. https:\/\/doi.org\/10.1038\/s41538-024-00367-7","journal-title":"NPJ Sci Food"},{"issue":"48","key":"1906_CR145","doi-asserted-by":"publisher","first-page":"6888","DOI":"10.3748\/wjg.v28.i48.6888","volume":"28","author":"YH Xu","year":"2022","unstructured":"Xu YH, Zhu WM, Guo Z (2022) Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease. World J Gastroenterol 28(48):6888\u20136899. https:\/\/doi.org\/10.3748\/wjg.v28.i48.6888","journal-title":"World J Gastroenterol"},{"issue":"3","key":"1906_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167648","volume":"1871","author":"J-C Xue","year":"2025","unstructured":"Xue J-C, Hou X-T, Zhao Y-W, Yuan S (2025) Biological agents as attractive targets for inflammatory bowel disease therapeutics. Biochimica Et Biophysica Acta (BBA)\u2014Molecular Basis Dis 1871(3):167648. https:\/\/doi.org\/10.1016\/j.bbadis.2024.167648","journal-title":"Biochimica Et Biophysica Acta (BBA)\u2014Molecular Basis Dis"},{"key":"1906_CR147","doi-asserted-by":"publisher","first-page":"108810","DOI":"10.1016\/j.intimp.2022.108810","volume":"108","author":"A Yaghoubi","year":"2022","unstructured":"Yaghoubi A, Amel JS, Reza Akbari EM, Ghazvini K (2022) Evaluation of the therapeutic effect of melittin peptide on the ulcerative colitis mouse model. Int Immunopharmacol 108:108810. https:\/\/doi.org\/10.1016\/j.intimp.2022.108810","journal-title":"Int Immunopharmacol"},{"key":"1906_CR148","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-012-0848-8","author":"R Yang","year":"2012","unstructured":"Yang R, Zhang S, Kong D, Gao X, Zhao Y, Wang Z (2012) Biodegradable polymer-curcumin conjugate micelles enhance the loading and delivery of low-potency curcumin. Pharm Res. https:\/\/doi.org\/10.1007\/s11095-012-0848-8","journal-title":"Pharm Res"},{"issue":"16","key":"1906_CR149","doi-asserted-by":"publisher","first-page":"15189","DOI":"10.1021\/acsnano.5c00700","volume":"19","author":"J Yang","year":"2025","unstructured":"Yang J, des Rieux A, Malfanti A (2025) Stimuli-responsive nanomedicines for the treatment of non-cancer related inflammatory diseases. ACS Nano 19(16):15189\u201315219. https:\/\/doi.org\/10.1021\/acsnano.5c00700","journal-title":"ACS Nano"},{"issue":"5","key":"1906_CR150","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/CM9.0000000000003026","volume":"137","author":"D Yao","year":"2024","unstructured":"Yao D, Ran Z (2024) New progress of small-molecule drugs in the treatment of inflammatory bowel disease. Chin Med J 137(5):556\u2013558. https:\/\/doi.org\/10.1097\/CM9.0000000000003026","journal-title":"Chin Med J"},{"key":"1906_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fgstr.2024.1386069","volume":"3","author":"A Yao","year":"2024","unstructured":"Yao A, Huang C, Wang X, Zhou R, Hao W, Lin Q (2024) The Reg protein family: potential new targets for the treatment of inflammatory bowel disease and colorectal cancer. Front Gastroenterol 3:1\u201310. https:\/\/doi.org\/10.3389\/fgstr.2024.1386069","journal-title":"Front Gastroenterol"},{"key":"1906_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114893","volume":"165","author":"S Yuan","year":"2023","unstructured":"Yuan S, Wang K-S, Meng H, Hou X-T, Xue J-C, Liu B-H, Cheng W-W, Li J, Zhang H-M, Nan J-X, Zhang Q-G (2023) The gut microbes in inflammatory bowel disease: future novel target option for pharmacotherapy. Biomed Pharmacother 165:114893","journal-title":"Biomed Pharmacother"},{"issue":"30","key":"1906_CR153","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.3748\/wjg.v26.i30.4378","volume":"26","author":"B Yue","year":"2020","unstructured":"Yue B, Yu Z-L, Lv C, Geng X-L, Wang Z-T, Dou W (2020) Regulation of the intestinal microbiota: an emerging therapeutic strategy for inflammatory bowel disease. World J Gastroenterol 26(30):4378\u20134393. https:\/\/doi.org\/10.3748\/wjg.v26.i30.4378","journal-title":"World J Gastroenterol"},{"issue":"7","key":"1906_CR154","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/ibd\/izy123","volume":"24","author":"M Zhang","year":"2018","unstructured":"Zhang M, Merlin D (2018) Nanoparticle-based oral drug delivery systems targeting the colon for treatment of ulcerative colitis. Inflamm Bowel Dis 24(7):1401\u20131415. https:\/\/doi.org\/10.1093\/ibd\/izy123","journal-title":"Inflamm Bowel Dis"},{"key":"1906_CR155","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01841","volume":"10","author":"L Zhang","year":"2019","unstructured":"Zhang L, Wei X, Zhang R, Petitte JN, Si D, Li Z, Cheng J, Du M (2019) Design and development of a novel peptide for treating intestinal inflammation. Front Immunol 10:1841. https:\/\/doi.org\/10.3389\/fimmu.2019.01841","journal-title":"Front Immunol"},{"key":"1906_CR156","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.818111","author":"WH Zhang","year":"2022","unstructured":"Zhang WH, Jin ZY, Yang ZH, Zhang JY, Ma XH, Guan J, Sun BL, Chen X (2022) Fecal microbiota transplantation ameliorates active ulcerative colitis by downregulating pro-inflammatory cytokines in mucosa and serum. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2022.818111","journal-title":"Front Microbiol"},{"issue":"1","key":"1906_CR157","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-023-01386-9","volume":"21","author":"K Zhang","year":"2023","unstructured":"Zhang K, Guo J, Yan W, Xu L (2023a) Macrophage polarization in inflammatory bowel disease. Cell Commun Signal 21(1):1\u201314. https:\/\/doi.org\/10.1186\/s12964-023-01386-9","journal-title":"Cell Commun Signal"},{"issue":"March","key":"1906_CR158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2023.1103617","volume":"14","author":"M Zhang","year":"2023","unstructured":"Zhang M, Li X, Zhang Q, Yang J, Liu G (2023b) Roles of macrophages on ulcerative colitis and colitis-associated colorectal cancer. Front Immunol 14(March):1\u201313. https:\/\/doi.org\/10.3389\/fimmu.2023.1103617","journal-title":"Front Immunol"},{"issue":"1","key":"1906_CR159","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40824-023-00412-8","volume":"27","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Lei H, Wang P, Zhou Q, Yu J, Leng X, Ma R, Wang D, Dong K, Xing J, Dong Y (2023c) Restoration of dysregulated intestinal barrier and inflammatory regulation through synergistically ameliorating hypoxia and scavenging reactive oxygen species using ceria nanozymes in ulcerative colitis. Biomater Res 27(1):75. https:\/\/doi.org\/10.1186\/s40824-023-00412-8","journal-title":"Biomater Res"},{"key":"1906_CR160","doi-asserted-by":"publisher","first-page":"1442876","DOI":"10.3389\/fphar.2024.1442876","volume":"15","author":"D Zhang","year":"2024","unstructured":"Zhang D, Jiang L, Yu F, Yan P, Liu Y, Wu Y, Yang X (2024) PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced colitis. Front Pharmacol 15:1442876. https:\/\/doi.org\/10.3389\/fphar.2024.1442876","journal-title":"Front Pharmacol"},{"issue":"March","key":"1906_CR161","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2024.1502849","volume":"11","author":"D Zhao","year":"2024","unstructured":"Zhao D, Ge A, Yan C, Liu X, Yang K, Yan Y, Hao M, Chen J, Daga P, Dai CC, Li C, Cao H (2024) T helper cell 17\/regulatory T cell balance regulates ulcerative colitis and the therapeutic role of natural plant components: a review. Front Med 11(March):1\u201323. https:\/\/doi.org\/10.3389\/fmed.2024.1502849","journal-title":"Front Med"},{"key":"1906_CR162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmolb.2022.996057","volume":"9","author":"L Zheng","year":"2022","unstructured":"Zheng L, Duan SL, Wen XL, Dai YC (2022) Molecular regulation after mucosal injury and regeneration in ulcerative colitis. Front Mol Biosci 9:1\u201319. https:\/\/doi.org\/10.3389\/fmolb.2022.996057","journal-title":"Front Mol Biosci"},{"issue":"2","key":"1906_CR163","doi-asserted-by":"publisher","DOI":"10.1007\/s42114-025-01292-3","volume":"8","author":"G Zheng","year":"2025","unstructured":"Zheng G, Zhang B, Yu H, Song Z, Xu X, Zheng Z, Zhao K, Zhao J, Zhao Y (2025) Therapeutic applications and potential biological barriers of nano-delivery systems in common gastrointestinal disorders: a comprehensive review. Adv Compos Hybrid Mater 8(2):227. https:\/\/doi.org\/10.1007\/s42114-025-01292-3","journal-title":"Adv Compos Hybrid Mater"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01906-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01906-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01906-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T04:14:23Z","timestamp":1758082463000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01906-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":163,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1906"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01906-8","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}